ArticleBMC cancer2021
A new rapid diagnostic system with ambient mass spectrometry and machine learning for colorectal liver metastasis.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Automatic recognition of Pd ions in high-resolution mass spectra of multicomponent samples without visible fine isotope structures.Nature communications · 2026Article
- Proteomic Differentiation of Colorectal Cancer From Normal Tissue via Ex Vivo E-Biopsy: A Novel Approach to Molecular Sampling for Diagnostic Precision.Cancer medicine · 2026Article
- Serum mass spectral fingerprints with machine learning for early discrimination of infectious pneumonia in the emergency department.BMC infectious diseases · 2026Observational
- Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025Review
- Applications of Artificial Intelligence for Metastatic Gastrointestinal Cancer: A Systematic Literature Review.Cancers · 2025Review
- Recent Developments in Machine Learning for Mass Spectrometry.ACS measurement science au · 2024Review
- [Diagnostic Study of Multi-spectral Intelligent Analyzer in Diagnosis of the Infiltration Degree of Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- New Diagnostic Modality Combining Mass Spectrometry and Machine Learning for the Discrimination of Malignant Intraductal Papillary Mucinous Neoplasms.Annals of surgical oncology · 2023Article
- Role of artificial intelligence in risk prediction, prognostication, and therapy response assessment in colorectal cancer: current state and future directions.Frontiers in oncology · 2023Review
- Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.BMC cancer · 2022Article
- Applications of ambient ionization mass spectrometry in 2021: An annual review.Analytical science advances · 2022Review
- Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases.World journal of gastroenterology · 2022Review
- Utility of mass spectrometry and artificial intelligence for differentiating primary lung adenocarcinoma and colorectal metastatic pulmonary tumor.Thoracic cancer · 2022Article
- The phospholipid membrane compositions of bacterial cells, cancer cell lines and biological samples from cancer patients.Chemical science · 2021Review
- Lipid Profiling in Cancer Diagnosis with Hand-Held Ambient Mass Spectrometry Probes: Addressing the Late-Stage Performance Concerns.Metabolites · 2021Review
- Rapid, Sensitive, and Versatile: A 5-Year Perspective on Applications of Ambient Ionization Mass Spectrometry in Bioanalytical Science.Mass spectrometry reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProbe electrospray ionization-mass spectrometry (PESI-MS) can rapidly visualize mass spectra of small, surgically obtained tissue samples, and is a promising novel diagnostic tool when combined with machine learning which discriminates malignant spectrum patterns from others. The present study was performed to evaluate the utility of this device for rapid diagnosis of colorectal liver metastasis (CRLM).
methodsA prospectively planned study using retrospectively obtained tissues was performed. In total, 103 CRLM samples and 80 non-cancer liver tissues cut from surgically extracted specimens were analyzed using PESI-MS. Mass spectra obtained by PESI-MS were classified into cancer or non-cancer groups by using logistic regression, a kind of machine learning. Next, to identify the exact molecules responsible for the difference between CRLM and non-cancerous tissues, we performed liquid chromatography-electrospray ionization-MS (LC-ESI-MS), which visualizes sample molecular composition in more detail.
resultsThis diagnostic system distinguished CRLM from non-cancer liver parenchyma with an accuracy rate of 99.5%. The area under the receiver operating characteristic curve reached 0.9999. LC-ESI-MS analysis showed higher ion intensities of phosphatidylcholine and phosphatidylethanolamine in CRLM than in non-cancer liver parenchyma (P < 0.01, respectively). The proportion of phospholipids categorized as monounsaturated fatty acids was higher in CRLM (37.2%) than in non-cancer liver parenchyma (10.7%; P < 0.01).
conclusionThe combination of PESI-MS and machine learning distinguished CRLM from non-cancer tissue with high accuracy. Phospholipids categorized as monounsaturated fatty acids contributed to the difference between CRLM and normal parenchyma and might also be a useful diagnostic biomarker and therapeutic target for CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.